November 21, 2018 | News

Soteria® featured on Europe’s leading biotech news website

Intract Pharma’s Soteria® technology was recently profiled on Europe’s leading biotech news website, Labiotech.eu. The article comments on the potential benefit of the Soteria® technology, highlighting that oral versions of existing antibody therapies “could make the treatments easier for patients and increase compliance.” Also discussed is the £1.4m grant awarded to Intract by Innovate UK to develop a scalable manufacturing process for an oral antibody product using Soteria®.

With over 100,000 monthly visitors to the website, Labiotech.eu covers the medical, industrial and food biotech sectors over a range of different platforms.

You can find the article here:

https://labiotech.eu/medical/intract-pharma-oral-immunotherapy/

You can also find Intract on Labiotech’s map of European Biotech companies here:

https://labiotech.eu/map/

 

Back to News